RxDoctor Payments Data

Cara McLeod, DO

Rheumatology · Marietta, GANPI 1205246246

Payments from drug & device makers

$5,560in general payments, 2019–2025

Across 258 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$826
  • Novartis$702
  • Johnson & Johnson$440
  • GSK$327
  • AstraZeneca$272
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$5,44598%
  • Education$1152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,560 in reported general payments places this provider in the 45th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$87,757
Medicare patients
171
Services billed
1,497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab63$426,754
Enbrel SureclickEtanercept19$153,223
OrenciaAbatacept16$93,239
ProliaDenosumab20$34,202
Hydroxychloroquine Sulfate143$4,951
Leflunomide50$4,145
Mycophenolic AcidMycophenolate Sodium12$3,360
Mycophenolate Mofetil22$3,181
MethotrexateMethotrexate Sodium150$2,990
Prednisone204$2,089
Allopurinol69$877
Colchicine19$716
Sulfasalazine18$334
Folic Acid26$264
Alendronate Sodium31$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Orencia$50$93,23916 claims
AmgenProlia$826$34,20220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →